临床放射学和神经病理学评估初级渐进性失言症
Dror Shir1, Nick Corriveau-Lecavalier1, Camilo Bermudez Noguera1
1Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Journal of neurology, neurosurgery, and psychiatry
|March 21, 2024
概括
初级渐进性失语 (PPA) 变体可以通过临床和神经成像特征进行区分. 使用FDG-PET扫描的机器学习算法准确地预测了PPA亚型的潜在神经病理.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 医疗成像医学成像
背景情况:
- 初级渐进性失言症 (PPA) 是一组神经退行性疾病,其特点是语言逐渐衰退.
- 三种PPA变体 - - 语义 (svPPA),语义 (agPPA) 和语义 (lvPPA) - - 与不同的病理有关:分别是TDP-43蛋白质病变,沉积和阿尔茨海默病.
- 准确区分PPA变异及其潜在病理对于了解疾病进展和开发向治疗至关重要.
研究的目的:
- 使用临床和神经成像特征来区分PPA变体.
- 评估不同PPA变体的进展模式.
- 评估结构性MRI和一种新的18-F氧葡萄糖正子发射断层扫描 (FDG-PET) 机器学习算法用于预测神经病理学的实用性.
主要方法:
- 分析了在1998年至2022年期间被诊断患有PPA的82名尸检患者.
- 对临床病史,语言特征,神经心理学结果和脑部成像数据的审查.
- 应用机器学习框架 (k-最近邻居分类器) 来对45名患者的FDG-PET扫描进行比较,与参考数据库进行比较.
主要成果:
- PPA变种分布:35 lvPPA (80%的阿尔茨海默病),28 agPPA (89%的病) 和18 svPPA (72%的FTLD-TDP).
- 语音失调与agPPA中的4R-tauopathy有关,而没有失调的纯粹的agrammatic PPA与3R-tauopathy相关.
- 基于FDG-PET的机器学习准确地预测了临床诊断和潜在病理,在每个变体中观察到不同的缩模式 (例如,svPPA-FTLD-TDP中的时极缩).
结论:
- 在agPPA中区分3R-tauopathy和4R-tauopathy可能取决于言语无力症的存在.
- 整合语言和临床特征可以提高PPA的神经病理学预测.
- 使用FDG-PET的数据驱动的大脑新陈代谢分解方法有效预测PPA变体的潜在神经病理.
更多相关视频
13:12Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
Published on: August 12, 2019
45.4K
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.0K
相关概念视频
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
